Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) GlobeNewswire Jul. 12, 2025 04:30 ...

Investing.com -- Ultragenyx Pharmaceutical (TADAWUL: 2070) Inc. (NASDAQ: RARE) stock fell over 5% after the company announced that the U.S. Food and Drug Administration (FDA) has issued a Complete ...

Investing.com -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock fell over 5% after the company announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter ...

NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a $2.77 billion market cap biotech company whose shares have declined over 22% in the past week, announced Friday that the U.S. Food and ...

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) Ultragenyx Pharmaceutical Inc. - GlobeNewswire - 32 minutes ago ...

The therapy has received multiple special designations including Regenerative Medicine Advanced Therapy and Fast Track in the U.S. 3rd party Ad. Not an offer or recommendation by Investing.com.

In this article, we proposed a novel Sample-adaptive Hierarchical medicAtion Prediction nEtwork, termed SHAPE, to tackle the above challenges in the medication recommendation task.